Redefining peptic ulcer as an H. pylori infection was a 'crime'; the real problem is low stomach acid, and acid blockers plus antibiotic 'triple therapy' are the wrong treatment.
Original statement
الراجل ده الجحش ده عمل نقله نوعيه وجريمه حول القرحه من ستريس وهو تعريف غلط اصلا خلاه عدوى | نقص افراز المعده موجود عند كل الناس اللي مش معايا دغري وسكه كده يعني اي حد اسم ضياء العوضي مش جنبه عنده نقص في حمض المعده ده مبدئيا بيشرب شاي بقى بيشرب كازوزه ا بيدي بياخد كونترلاك بياخد نيكسيوم بياكل دقيق بياكل مكرونه بياكل اندومي اي دقيق ابيض ولازق على الجدار الاتش س ال بتاعك اقل من الطبيعي
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Redefining peptic ulcer as an H. pylori infection was a 'crime'; the real problem is low stomach acid, and acid blockers plus antibiotic 'triple therapy' are the wrong treatment.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! الجرثومة (Open source)
- Published
- 8 December 2025
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Machine-generated or CC transcript of a live stream; wording may contain transcription errors; context is conversational. original_ar joins separate verbatim passages with ' | '.
- Claimed mechanism
Ulcers come from stress/diet and hypochlorhydria; bacteria are not the cause.
- Claimed health effect
Unnecessary antibiotic and PPI use.
- Population concerned
People with H. pylori or ulcers.
- Geographic restriction by Elawady
none found
Diverging source versions
نقص افراز المعده موجود عند كل الناس اللي مش معايا دغري وسكه كده يعني اي حد اسم ضياء العوضي مش جنبه عنده نقص في حمض المعده ده مبدئيا بيشرب شاي بقى بيشرب كازوزه ا بيدي بياخد كونترلاك بياخد نيكسيوم بياكل دقيق بياكل مكرونه بياكل اندومي اي دقيق ابيض ولازق على الجدار الاتش س ال بتاعك اقل من الطبيعي
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! الجرثومة (Open source)
- Published
- 8 December 2025
- Timestamp
- 0:42:08 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
بيشرب شاي بقى بيشرب كازوزه ا بيدي بياخد كونترالاك بياخد نيكسيوم بياكل دقيق بياكل مكرونه بياكل اندومي اي دقيق ابيض ولازق على الجدار الاتش سي ال بتاعك اقل من الطبيعي خلاص بنسميها الاكلوروهايد
He drinks tea, drinks soda, takes Controloc, takes Nexium, eats flour, eats pasta, eats Indomie - any white flour, stuck on the wall - your HCl is lower than normal; we call it achlorhydria.
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- حقيقه جرثومه المعده . #ضياء_العوضي (Open source)
- Published
- 15 December 2025
- Timestamp
- 0:31:21 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; wording may contain speech-recognition errors; speaker turns are not marked, the excerpt was judged to be Elawady's own speech from context.
Scientific assessment
False – The statement contradicts the robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
H. pylori as ulcer cause is a scientific crime; low acid is the real cause.
2. What is demonstrably correct?
Rising antibiotic resistance is a real challenge, and stress, NSAIDs and other factors also contribute to ulcers.
3. What is wrong or exaggerated?
Randomised trials show that curing H. pylori prevents ulcer recurrence and reduces gastric cancer; the bacterium is formally recognised as an infectious disease (ICD-11).
4. What remains unclear?
Optimal regimens vary by local resistance patterns.
5. Which studies support it?
None.
6. Which studies contradict it?
Ford 2016 Cochrane (I-GUT-02), Ford 2020 (I-GUT-03), Maastricht VI (I-GUT-01).
7. What applies to Germany and Europe?
European guidelines follow Maastricht VI.
8. What is known about Egypt?
H. pylori infection is common in many countries; local resistance patterns matter. No Egypt-specific data were reviewed.
9. What practical conclusion is appropriate?
People with H. pylori-related ulcers benefit from eradication therapy; refusing it raises the risk of recurrent ulcers, bleeding and gastric cancer.
Assessment details
- Rationale for certainty of evidence
Cochrane review of RCTs: eradication therapy greatly reduces duodenal and gastric ulcer recurrence versus no treatment (RR 0.20 and 0.31); RCT meta-analysis: eradication reduces gastric cancer incidence (RR 0.54) and gastric cancer mortality (RR 0.61) in healthy infected people (mostly East Asian trials). The Maastricht VI consensus treats H. pylori as an infectious disease that should be treated.
- Source quality
Video statement contradicting well-established, RCT-confirmed evidence.
- Regional transferability
High; trials span many countries.
- Individual exceptions
Antibiotic resistance makes regimen choice important.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: Is H. pylori not the cause of peptic ulcer (with low acid being the real problem), and are eradication and acid suppression the wrong treatment?
Research question in detail (PICO)
- Population
- H. pylori-positive people with or without peptic ulcer
- Intervention or exposure
- Eradication therapy (antibiotics plus acid suppression)
- Comparison
- No eradication / placebo
- Geographic scope
- universal biology; antibiotic resistance region-specific (Egypt)
- Outcomes
- Ulcer recurrence
- Gastric cancer incidence and mortality
- Eradication success
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Antibiotic resistance makes some H. pylori treatments fail
Savoldi A et al.. Gastroenterology 2018 · PMID 29990487 · DOI 10.1053/j.gastro.2018.07.007 Meta-analysisabstract checkednewly addedGlobal meta-analysis: high H. pylori resistance makes clarithromycin triple therapy fail far more often.
- Actual result
- Resistance >=15% in most WHO regions; failure OR 6.97 (5.23-9.28)
- Methodological quality
- moderate
- Relevance
- indirect: supports regimen criticism only
- Limitations
- Heterogeneous
H. pylori treatments in Egypt cure about 70-79%
Shekeban YM et al.. Sci Rep 2025 · PMID 40341536 · DOI 10.1038/s41598-025-98606-8 Randomised controlled trialabstract checkednewly addedEgyptian RCT: standard triple therapy eradicated H. pylori in 70% per protocol.
- Actual result
- 70% vs 76-79% with vonoprazan regimens
- Methodological quality
- low (open label)
- Relevance
- regional; regimen criticism only
- Limitations
- Small, per-protocol
What speaks against the claim?
Treating H. pylori prevents ulcers returning (Cochrane)
Ford AC et al.. Cochrane Database Syst Rev 2016 · PMID 27092708 · DOI 10.1002/14651858.CD003840.pub5 Meta-analysisabstract checkedCochrane review of RCTs: eradication greatly reduces duodenal and gastric ulcer recurrence.
- Actual result
- RR 0.20 and 0.31
- Methodological quality
- high
- Relevance
- direct
- Limitations
- Older trials
Treating H. pylori prevents stomach cancer
Ford AC et al.. Gastroenterology 2025 · PMID 39824392 · DOI 10.1053/j.gastro.2024.12.033 Meta-analysisabstract checkednewly addedUpdated meta-analysis of 11 RCTs: eradication reduces gastric cancer and gastric cancer death.
- Actual result
- RR 0.64 (0.48-0.84); mortality RR 0.78 (0.62-0.98)
- Methodological quality
- high
- Relevance
- direct
- Limitations
- Overlaps with I-GUT-03
UK guideline on heartburn and indigestion
National Institute for Health and Care Excellence (NICE). NICE guideline CG184 2014 (last updated 18 October 2019) Guideline / position statementfull text checkednewly addedNICE CG184 recommends eradication for H. pylori-positive peptic ulcer.
- Actual result
- Recommendation 1.7.1
- Methodological quality
- official guideline
- Relevance
- direct
- Limitations
- UK
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
H. pylori causes most peptic ulcers and contributes to gastric cancer; eradication prevents recurrence and cancer. The criticism of standard clarithromycin triple therapy has a factual basis where resistance is high (including Egypt), which argues for better regimens, not against treatment.
Why some studies weigh more
Cochrane and RCT meta-analyses dominate; resistance data are relevant only to regimen choice. Overlapping meta-analyses (I-GUT-03, I-GUT-122) counted once.
Is a causal relationship established? Yes, established RCTs show that removing the bacterium prevents ulcer recurrence and cancer.
Remaining uncertainty
Optimal regimen in Egypt.
Justified conclusion
False; the only correct element is that empiric triple therapy is often suboptimal because of resistance.
Why do studies seem to disagree?
No real conflict: resistance studies concern how to treat, eradication trials concern whether to treat.
Does this depend on the country?
- General biological effects
- Universal.
- Eating habits
- Not relevant.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Antibiotic availability without prescription in Egypt may favour resistance (not quantified here).
- Actual monitoring data
- Egyptian eradication RCT (I-GUT-112): 70-79% eradication.
A regional difference is supported by robust data.
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Ulcer recurrence and gastric cancer after eradication
- Starting level
- high (randomised trials)
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- NICE: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184; I-GUT-108) (2014, updated 2019) · Original publication
Lifestyle advice (healthy eating, weight reduction, smoking cessation; avoid personal precipitants; main meal well before bed); step down PPIs to lowest effective dose or as-needed unless an underlying condition or comedication needs continuing treatment; same-day referral for dyspepsia with significant acute GI bleeding; long-term full-dose PPI after oesophageal stricture dilatation and as maintenance for severe oesophagitis; H. pylori eradication for H. pylori-positive peptic ulcer; PPI co-prescription with NSAIDs in high-risk people.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | (hypochlorhydria OR "low gastric acid" OR "low stomach acid") AND ("peptic ulcer" OR "duodenal ulcer") AND (cause OR pathogenesis) | supporting evidence | 1066 | |
| PubMed (E-utilities esearch) | 26 October 2026 | (achlorhydria[mh] OR hypochlorhydria[tiab]) AND (peptic ulcer[mh]) AND (etiology[sh]) | supporting evidence | 163 | |
| PubMed (E-utilities esearch) | 26 October 2026 | (helicobacter infections[mh]) AND (peptic ulcer[mh]) AND (eradication) AND (systematic review[pt] OR meta-analysis[pt]) AND 2018:2026[dp] | contradicting evidence | 10 | |
| PubMed (E-utilities esearch) | 26 October 2026 | (proton pump inhibitors[mh]) AND (neoplasms[mh] OR depression[mh] OR erectile dysfunction[mh] OR infertility[mh] OR autoimmune diseases[mh]) AND (meta-analysis[pt] OR cohort[tiab]) AND 2020:2026[dp] -> screening surfaced PMID 39824392 (Ford 2025), verified by efetch | contradicting evidence | 186 | |
| Europe PMC | 26 October 2026 | "Helicobacter pylori" AND (Egypt OR Egyptian) AND (clarithromycin OR "triple therapy") AND (resistance OR eradication) | supporting evidence | 586 | |
| Europe PMC | 26 October 2026 | "Helicobacter pylori" AND (Egypt OR Egyptian OR "Middle East" OR Arab) AND ("antibiotic resistance" OR "antimicrobial resistance") AND ("meta-analysis" OR "systematic review") | supporting evidence | 508 | |
| Europe PMC | 26 October 2026 | TITLE:"Helicobacter pylori" AND TITLE:(Egypt OR Egyptian) AND (resistance OR eradication OR clarithromycin) | both directions | 28 | |
| Web (curl/WebFetch of guideline page) | 26 October 2026 | https://www.nice.org.uk/guidance/cg184/chapter/1-Recommendations | guidelines | 1 |
Open questions
Current Egyptian resistance rates and best first-line regimen.
How deeply was this checked?
7 linked studies: 1 checked in full text (0 of them with a structured risk-of-bias assessment), 6 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: False (high)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: False (high)
Updated meta-analysis confirms; resistance data acknowledged as the correct element.
New sources: I-GUT-108 I-GUT-111 I-GUT-112 I-GUT-122
In plain language
The discovery that a bacterium, H. pylori, causes most stomach and duodenal ulcers changed medicine. Trials show that treating the infection prevents ulcers from coming back and lowers the risk of stomach cancer. Calling this discovery a crime contradicts strong evidence.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (5)
-
Treating H. pylori prevents ulcers returning (Cochrane)
Ford AC et al.. Cochrane Database Syst Rev 2016 · PMID 27092708 · DOI 10.1002/14651858.CD003840.pub5Meta-analysisindependent cross-checkabstract checked★ key studyDuodenal ulcer recurrence fell from 64% without treatment to 13% with eradication.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Ulcer treatment.
- How was the study done?
Cochrane review.
- How many people, animals or samples were studied?
Thousands.
- What was actually found?
Fewer recurrences.
- How large was the observed effect?
RR 0.20.
- What do the results mean in everyday life?
Eradication works.
- What are the study's limitations?
Older trials.
- What does it say about Elawady's specific claim?
Contradicts C-GUT-06.
- Do the results apply to Germany and Europe?
Applicable.
-
H. pylori treatment and stomach cancer
Ford AC et al.. Gut 2020 · PMID 32205420 · DOI 10.1136/gutjnl-2020-320839Meta-analysisindependent cross-checkabstract checkedEradication nearly halved gastric cancer incidence in trials.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
GC prevention.
- How was the study done?
MA of RCTs.
- How many people, animals or samples were studied?
10,164.
- What was actually found?
Fewer cancers.
- How large was the observed effect?
RR 0.54.
- What do the results mean in everyday life?
Treating infection prevents cancer.
- What are the study's limitations?
East Asian.
- What does it say about Elawady's specific claim?
Contradicts C-GUT-06.
- Do the results apply to Germany and Europe?
Moderate.
-
Maastricht VI: H. pylori management
Malfertheiner P et al.. Gut 2022 · PMID 35944925 · DOI 10.1136/gutjnl-2022-327745Guideline / position statementindependent cross-checkabstract checkedH. pylori is an infectious disease; infected people should be treated.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
H. pylori guidance.
- How was the study done?
Consensus.
- What was actually found?
Treat all infected.
- What do the results mean in everyday life?
Treatment is standard.
- What are the study's limitations?
Consensus; COI.
- What does it say about Elawady's specific claim?
Contradicts C-GUT-06.
- Do the results apply to Germany and Europe?
European.
-
UK guideline on heartburn and indigestion
National Institute for Health and Care Excellence (NICE). NICE guideline CG184 2014 (last updated 18 October 2019)Guideline / position statementindependent cross-checkfull text checked★ key studyNICE advises lifestyle changes and the lowest effective dose of acid blockers, but long-term full-dose treatment for severe inflammation or a narrowed gullet.
H. pylori eradication recommended in peptic ulcer
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Guide care of reflux and indigestion.
- How was the study done?
National guideline.
- How many people, animals or samples were studied?
Adults in England.
- What was actually found?
Lifestyle first; step down PPIs; keep PPIs for stricture/severe oesophagitis; eradicate H. pylori in ulcers.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Diet matters, but some people need acid blockers long term.
- What are the study's limitations?
Older evidence base for some statements.
- What does it say about Elawady's specific claim?
Contradicts a blanket ban on acid blockers.
- Do the results apply to Germany and Europe?
Applies directly to Europe.
- What can explicitly not be concluded from this study?
Not an evidence synthesis for each claim.
-
Treating H. pylori prevents stomach cancer
Ford AC et al.. Gastroenterology 2025 · PMID 39824392 · DOI 10.1053/j.gastro.2024.12.033Meta-analysisindependent cross-checkabstract checkedIn randomised trials, clearing H. pylori lowered stomach cancer by about a third and stomach cancer deaths by about a fifth.
Eradication reduces gastric cancer (RR 0.64) and deaths (RR 0.78) in RCTs
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Update evidence on eradication and gastric cancer.
- How was the study done?
Meta-analysis of RCTs and observational studies.
- How many people, animals or samples were studied?
11 RCTs, 13 observational studies.
- What was actually found?
Fewer cancers and cancer deaths after eradication.
- How large was the observed effect?
RR 0.64 incidence; 0.78 mortality.
- What do the results mean in everyday life?
Treating the infection protects against stomach cancer.
- What are the study's limitations?
Regional mix of trials.
- What does it say about Elawady's specific claim?
Contradicts the claim.
- Do the results apply to Germany and Europe?
Applicable; lower baseline risk in Europe.
- What can explicitly not be concluded from this study?
Cannot give exact absolute benefit for Egypt.
No study in this group is marked as key.
Studies with mixed or unclear results (2)
-
Antibiotic resistance makes some H. pylori treatments fail
Savoldi A et al.. Gastroenterology 2018 · PMID 29990487 · DOI 10.1053/j.gastro.2018.07.007Meta-analysisindependent cross-checkabstract checkedIn many regions, more than 15% of H. pylori bacteria resist key antibiotics, and resistance makes standard triple therapy fail far more often.
Triple therapy failure due to resistance is real; eradication itself remains indicated
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Map H. pylori resistance.
- How was the study done?
Meta-analysis.
- How many people, animals or samples were studied?
66,142 isolates, 65 countries.
- What was actually found?
Resistance >=15% in most regions; clarithromycin resistance raises failure risk.
- How large was the observed effect?
OR 6.97 for failure.
- What do the results mean in everyday life?
Doctors need to choose treatment based on local resistance.
- What are the study's limitations?
Heterogeneous data.
- What does it say about Elawady's specific claim?
Partly supports the criticism of 'triple therapy'; not of treating H. pylori.
- Do the results apply to Germany and Europe?
Europe has its own resistance data.
- What can explicitly not be concluded from this study?
Cannot show that H. pylori does not cause ulcers.
-
H. pylori treatments in Egypt cure about 70-79%
Shekeban YM et al.. Sci Rep 2025 · PMID 40341536 · DOI 10.1038/s41598-025-98606-8Randomised controlled trialindependent cross-checkabstract checkedIn an Egyptian trial, standard triple therapy cleared H. pylori in 70% and vonoprazan-based regimens in 76-79% of those who completed treatment.
Standard triple therapy ~70% eradication in Egypt (suboptimal), not evidence against eradication
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare H. pylori regimens in Egypt.
- How was the study done?
Open-label RCT.
- How many people, animals or samples were studied?
Egyptian adults (n not in abstract).
- What was actually found?
Eradication 70%, 76%, 79%; no significant difference.
- How large was the observed effect?
70% vs 79%.
- What do the results mean in everyday life?
Standard treatment in Egypt fails in about 3 in 10 people who complete it.
- What are the study's limitations?
Small, open-label.
- What does it say about Elawady's specific claim?
Supports regimen criticism, not denial of H. pylori.
- Do the results apply to Germany and Europe?
Not European data.
- What can explicitly not be concluded from this study?
Cannot show ulcers are not caused by H. pylori.
No study in this group is marked as key.
Regional context
Germany / EU
European guidelines follow Maastricht VI.
Egypt
H. pylori infection is common in many countries; local resistance patterns matter. No Egypt-specific data were reviewed.
What applies in my country?
General scientific assessment
False False: treating H. pylori prevents ulcer recurrence and reduces stomach cancer risk.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.. Ford AC et al.. Cochrane Database Syst Rev 2016 · PMID 27092708 · DOI 10.1002/14651858.CD003840.pub5
- Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis.. Ford AC et al.. Gut 2020 · PMID 32205420 · DOI 10.1136/gutjnl-2020-320839
- Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.. Malfertheiner P et al.. Gut 2022 · PMID 35944925 · DOI 10.1136/gutjnl-2022-327745
- Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (NICE guideline CG184). National Institute for Health and Care Excellence (NICE). NICE guideline CG184 2014 (last updated 18 October 2019)
- Eradication Therapy to Prevent Gastric Cancer in Helicobacterpylori-Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.. Ford AC et al.. Gastroenterology 2025 · PMID 39824392 · DOI 10.1053/j.gastro.2024.12.033
- Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.. Savoldi A et al.. Gastroenterology 2018 · PMID 29990487 · DOI 10.1053/j.gastro.2018.07.007
- Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial.. Shekeban YM et al.. Sci Rep 2025 · PMID 40341536 · DOI 10.1038/s41598-025-98606-8